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Abstract
In the current methodology of fighting infections, antibiotics are used to
eliminate the invading bacteria. A result of this process is constantly evolving antibiotic
resistant bacteria. If we hope to be more effective at preventing disease, we must shift
the way we view microbial treatment. One novel method of preventing bacterial
proliferation is the modulation of biofilm. Many bacteria can produce a biofilm; an
extracellular substance that provides protection and antibiotic resistance to the
bacteria. Attacking this biofilm and allowing the body's natural defenses to clear out the
bacteria is one promising way to treat bacterial infections while avoiding adaptive
bacterial mutation.
lsatin has been shown to regulate biofilm and thus exhibits properties similar to
quorum sensing molecules. Additionally, isatin derived from indole which is a known
quorum sensing molecule. Previous studies have shown that hydrazone and oxime
derivatives of isatin have antimicrobial properties, which make them targets of interest
in testing the ability of isatins to regulate biofilms. Within this study, a library of these
compounds was created and tested against E. coli, P. aeruginosa, 5. aureus to determine
the 0D 600 correlation, minimum inhibitory concentration and the effect the compounds
have on biofilm formation. For E. coli it was found that a compound was found to inhibit
while others promoted. For P. aeruginosa, it was found that a compound was found to
inhibit biofilm production, while two others were found to be promoters. Compounds
were found to be biofilm inhibitors for 5. aureus, while a compound was found to be a
promoter.
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Introduction
1
Since the discovery of penicillin in 1928, the default clinical methodology when
treating an infection has been to identify the bacterial pathogen responsible and
subsequently cause bacterial death using an antibiotic. This routine stress on
reoccurring bacterial strains has had the unexpected consequence of causing the rapid
evolution of clinically significant bacteria strains. Resistance to any novel antibiotic is
observed within a few years of the antibiotic's introduction into the commercial
2

market .
When a colony of bacteria is dosed with an antibiotic it is susceptible to,
bacterial death results. There also exists the possibility a single bacterium survives then
this bacterium proliferates and spreads the mutation. Since bacteria are able to transfer
genetic material easily and thus mutate quickly. This causes bacterial-resistance to an
antibiotic. When this new strain of bacteria infects a host, the antibiotic that worked on
its predecessor will no longer be as effective on the new strain due to its new innate
resistance.3 The speed at which bacterial evolution occurs is problematic as new
antibiotics cannot be either found or synthesized as quickly as bacteria are becoming
resistant to the old ones.
4

This emerging medical arms-race is forced by the new bacterial threats that live
among

us

today.

The

most

well-known

"superbug"

is

methicillin-resistant

Staphylococcus aureus (MRSA). It is best recognized for the widespread outbreak of
MRSA in 2005 within the United States.

5

The outbreak resulted in 270,000

hospitalizations and more than 18,000 deaths. The creation of this "superbug" was a
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result of the laisse-faire attitude toward antibiotics within the agricultural industry.
Farmers and ranchers give millions of pounds of antibiotics to livestock in order to make
them grow faster and to prevent diseases. This caused a treatable strain, Staphylococcus
aureus CC398, to develop resistance to methicillin and tetracycline, the two most
common antibiotics used to treat 5. aureus infections, which has made fighting MRSA
incredibly difficult.

5

In light of our current understanding of bacterial resistance, the traditional view
of how to treat microbial infection must be set aside in order to become more effective
at combating bacterial resistance. The customary approach to considering how an
antibiotic should function is the first to be reconsidered. Traditional antibiotics act by
hindering bacterial functions such as cell wall synthesis, DNA replication, RNA
transcription, and protein synthesis which are essential for proper logarithmic growth in
3

vitro. Cell wall synthesis is disrupted by P-lactams and glycopeptides; P-lactams block
the cross-linking of peptidoglycan by barring the peptide bond formation reaction
catalyzed by

transpeptidases while

glycopeptides

act as

steric

inhibitors of

peptidoglycan maturation. Both of these processes reduce the cell wall's mechanical
6
strength. Quinolones obstruct DNA synthesis by forming a stable interaction complex
between drug-bound topoisomerase enzyme and cleaved DNA, trapping the DNA at the
6
cleavage stage and preventing strand rejoining. The inhibition of RNA synthesis is
caused by the rifamycin class of antibiotics, by inhibiting DNA-dependent transcription
by binding to the subunit of a DNA-bound and actively-transcribing RNA polymerase
6
enzyme. Protein synthesis is repressed by 50S ribosome and 30S ribosome inhibitors;
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SOS inhibitors work by physically blocking the initiation of protein synthesis translation
or translocation of peptide chain, and 30S inhibitors work by blocking the access of
aminoacyl-tRNAs. These antibiotics have a history of being highly effective, yet the
threat of a post-antibiotic era still looms.
The common feature amongst all these antibiotics is that they target
biosynthetic processes that are only present in growing bacteria. Therefore, antibiotics
that specialize in killing growing or multiplying cells cannot kill non-multiplying bacteria.

7

Contrary to traditional methods, novel treatments are aimed at disarming bacterial
defenses. 2 These new molecules deactivate different types of virulence mechanisms
such as toxin function, toxin delivery, bacterial adhesion, and virulence regulation.
Direct inhibition of a toxin function is the basis for antitoxins for, among others,
diphtheria, botulinus, and tetanus. These inhibitors focus specifically on the proteins
secreted by the pathogen in question. An alternative method would be to block the
downstream effects of the particular toxin by targeting the host proteins. For example,
8

one study found that the defective cAMP-activated

er

channel, which causes cystic

fibrosis in affected individuals, can be used to block secretory diarrheas and cholera by
inhibiting

er

channels within a host. Bacterial toxin delivery

2

can be targeted by

interfering with the proper delivery of the toxin to its action site. The customary method
is to create a compound which simply binds to the particular toxin in question thus
inhibiting the toxin's binding ability. An example of this is the inhibition of adhesion
which is a prerequisite to toxin production. Regulating the expression of virulence is
attractive because it would prevent the formation of the toxin. The specific methods
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used to inhibit the mechanisms for virulence factors will vary between bacterial species,
however their disruption disable the bacteria's symptomatic triggers until the bacteria is
dispersed by the hosts immune response. This concept of non-bactericidal regulation of
infection needs to be considered as it limits the evolutionary stress that cell death
causes.
As opposed to directly affecting the expression of virulence factors, influencing
the biofilm stage of a bacterium's lifecycle will indirectly influence the development of
virulence, as it occurs within a later stage of development. Biofilms are a good target
for treatment because the main portion of a bacterium's lifecycle is spent within one
and often are the cause of toxin expression, slow cell proliferation, increased genetic
transfer, and inhibited host immune effectiveness. Biofilms are aggregates of bacteria
within a matrix of extracellular polymeric substances (EPS) which is formed from various
biopolymers. Contrary to the common notion that bacteria are only planktonic, the
biofilm aggregates are stationary communities and begin as surface-attached bacteria.
These communities can contain either one or multiple species of bacteria which act in
9
concert with each other. These initially adhered bacteria begin producing EPS which
attracts other bacteria to the same site. While bacteria are collecting within the biofilm,
the bacteria already present are proliferating new bacteria. Once the biofilm has
reached maturity, the biofilm releases them into the surrounding environment, allowing
them to colonize new ones.
Seeing how biofilms account for over 80% of microbial infections in humans and
can contribute to heart diseases, lower respiratory diseases, and a variety of others,
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their creation would seem a likely target for a new treatment strategy . The biofilm
matrix is over 90% of the dry mass of the biofilm and creates a skeleton for the three
dimensional structure of the biofilm, while also allowing for better adhesion to surfaces.
The matrix is comprised of biomolecules such as proteins, carbohydrates, and DNA.
Within the matrix individual bacterium are immobile, instead of planktonic, and held in
close proximity to each other, allowing for better cell-to-cell communication and the
transfer of genetic material.

11

This leads to an increased rate of developing resistance.

Bacteria existing in the biofilm communities are exceedingly more resistant to standard
antibiotic treatment. This is thought to be due to decreased penetration or solubility of
the antibiotic into the matrix. Additionally the safety of the biofilm leads many cells to
decrease in growth-rate or cease altogether persistence. This leads to a defense against
antibiotics to achieve cell growth.
One avenue to influencing the creation of a biofilm is by inhibiting quorum
sensing. Quorum sensing is the regulation of gene expression as a reaction to fluxes in
cell-population density. The bacteria produce and release chemical signal molecules,
known as autoinducers, and change their response to the surrounding based on the
concentration of the autoinducer. Thus as cell density increases the autoinducer
concentration increases and the bacteria respond. Once a minimum concentration is
detected by a bacterium, the stimulus of an autoinducer leads to a change in gene
expression within the bacterium. There are two main classes of autoinducers:
oligopeptides and N-acyl homoserin lactones (AHL). The bacterial response to these two
classes varies by strain; however, there is a universal autoinducer Autoinducer-2, a

Nuckolls 10
furanosyl borate diester, which demonstrates biofilm up-regulation in most species of
bacteria.

12

It is thought that this autoinducer is the remaining element of an initial

system. These two main subclasses of autoinducers exist because while quorum sensing
pathways have been kept relatively conserved through bacterial evolutions, the
molecules used as signals were changed. These changes are a response to an innate
proclivity for bacterial strains to reside with some strains but not with others. If one
bacterial stain produces a waste product that is harmful for another, the first will not
grow well in contact with the second. To avoid this, the bacteria learn to recognize the
quorum sensing signals from bacteria they cannot live with as a sign to disperse the
biofilm they have created and move elsewhere. 13
Bacteria use quorum sensing to regulate a wide variety of physiological activities,
including virulence and biofilm formation

13

.

This allows for an opportunity to exploit

such as a system, much like jamming a communication signal. The synthesis of a
molecule mimicking the shape of known autoinducers, so that the synthesized molecule
would be accepted by the bacterium and ultimately cause confusion. Ideally such a
molecule would be a mock-autoinducer but differ enough that it would not trigger the
same response that the native autoinducer does. Although the quorum sensing system
is conserved for all bacteria, the signal relay mechanisms, specific chemical signals, and
particular target genes involved change per species and strain. For example, a molecule
which is considered an autoinducer and decreases biofilm for one bacterial strain may
up-regulate the biofilm in another. Even with this complication, the signaling systems
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are similar enough that an autoinducer which affects one bacterial strain can make for a
good testing target for other strains and species of bacteria.
lndole (Figure 1) is a metabolite of the amino acid tryptophan and has recently
been found to participate in signaling biofilm formation as an autoinducer with some
14
involvement in quorum sensing. In particular, indole is found in large quantities in at
15

least 85 bacterial species, many of which are pathogenic . This widespread abundance
of indole may indicate its broad-spectrum recognition by bacterial strains in the form of
a third autoinducer system or subsystem. Within Escherichia coli indole promotes
bacterial secretion of toxins, helps maintain genetic stability, and plays a role as an
active signal in metabolic control. Additionally, indole is thought to be a chemo
repellant, which is a chemical substance which decreases motility, thus affecting the
bacteria's ability to colonize. The oxidized form of indole, isatin (Figure 1), is also a found
within same biological systems and may also influence biofilm formation. lsatin is
thought to be a downstream metabolite of indole and has been found to be a biofilm
regulator

within

E.

coli strains,

Enterohemorrhagic Escherichia coli.

16

decreasing

biofilm

formation

for

The specific pathways which form endogenous

isatin still require further experimental effort.

�

0

� NI
lndole

four-fold

lsatin

Figure 1: Structures of indole and isatin
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Current literature has shown on the effect oxidized indole derivatives and isatin
itself have on biofilm regulation.

17

It may be possible that drugs containing an isatin

derivative could compete with endogenous isatin, and the derivative then influences
biochemical pathways where isatin is involved.

17

lsatin derivatives have been found to

act as inhibitors of apoptosis, anticonvulsants, and other antiviral, anti-bacterial, and
anti-fungal agents.

18

There is proof that isatin is a bimolecular product of human

cytochrome P450-catalyzed metabolism of indole and thus not a result of non
enzymatic oxidation

19

.

Thus a mock-isatin derivative may interplay with biochemical

processes in which isatin plays a role. We hope to confirm the pervious observations
that isatin has influence on biofilm formation. The focus for this study was the
development and testing of isatin and isatin derivatives focusing on the substitution of
the 3-oxo carbonyl for hydrazone. Hydrazone derivatives were chosen due to their
previously researched biological activity and antimicrobial properties.

20

Previously

synthesized derivatives were found to have a bactericidal effect on both Gram negative
and Gram positive bacteria. Compounds 1 and 2 are (Figure 2) derivatives taken from
literature.

21

The addition of an anti-microbial property to isatin could be useful.
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Figure 2: Structures of isatin derivatives
J. Lee, et. al. found isatin had an effect on biofilm formation for both E. coli
strains and Pseudomonas aeruginosa

15

while hydrazone derivatives were found to have
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significant antibiotic activity against Staphylococcus aure us.

21

In particular, compound 2

was found to be active against Staphylococcus bacteria at a minimum inhibitory
concentration (MIC) of 204 µg/ml and compound 1 was found to be active at a MIC of
106 µg/ml for Staphylococcus aureus.

21

Thus, E. coli, P. aeruginosa, and 5. aureus were

chosen as targets for the created derivatives due to their ubiquity in nature and the
previously stated applications.
To accurately investigate biofilm inhibition, it first has to be established whether
the derivative in question is a bactericidal compound. This requires the use of minimum
inhibitory concentration (MIC) assays to assess the lowest concentration at which a
particular compound visually prevents growth of the test strain of bacteria. Only after
this concentration is established can biofilm inhibition be investigated since effects on
biofilm can only be confirmed below the compound's ability to inhibit cell growth.
Inhibition assays examine how a bacteria's ability to form biofilm is affected by the
addition of a compound. Providing insight into whether the compound in question could
be used for the treatment of that particular bacterial species in the event of an
infection. The results of this test were quantified through the use of UV - Visible
spectrometry, after washing away the media containing planktonic bacteria and Gram
staining the biofilm adhered to the bottom of the well. This data is expressed through
the use of the half maximal inhibitory concentration (IC50 ). An IC50 value denotes the
concentration required to inhibit a biochemical process by half. Within these
experiments the tested process was biofilm formation. This found value is used by the
pharmacological industry as a unit to specify the in vitro efficiency of a drug.
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Special considerations must be made when testing inhibition of a compound
near its MIC. If the compound is bactericidal then it could be killing some of the bacteria
at the start of the assay. The compound could also be bacteriostatic, thus disable the
bacteria and not allow for cell proliferation. Investigating the possibility of this would
require growth curve analysis, where the 0D 600 of both the dosed and pure bacterial
solutions would be tested every hour. This observation of growth vs. time allows us to
determine if biofilm decrease is a consequence of delayed growth.
The final consideration for this investigation is how the toxicity of the
compounds in question would be tested in order to determine if they are fit to be used
in mammalian systems. The compounds in question would be tested against a
eukaryote to determine if they are toxic within the small-scale before any further
determinations are made. If it is found that the compound is toxic, a biofilm inhibitor
would still have limited use within industry for such things as the coating for waste
water pipes, paints, and plastic impregnation.

Results and Discussion
In order to investigate whether isatin or hydrazone derivatives had an effect on
biofilm, the synthesis of a library of isatin derivatives was first carried out. These
derivatives were then placed through biological testing by first correlating the colony
counts with optical density to allow for quick bacterial concentration determination for
both assays. Thereafter, the isatin compounds were investigated through the use of the
MIC and biofilm inhibition assay to examine if biofilm would form with the tested
compound present.
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Synthesis of library
Compounds 1, 2 and 4 were synthesized via condensation with the appropriate
hydrazide derivative (Scheme 1).
catalyzed condensation.

Thiourea derivative 2 was found to require acid

This was not necessary for 1 presumably because the

hydrazide reagent was a salt. Due to multiple nitrogens, the guanidine derivative 3 could
not be synthesized using the same condensation method so a di-tert-butoxycarbonyl (di
Boc) protection pathway was used (Scheme 2).

0

1 drop HCI
EtOH

z

96.7%

0

�

)-o�N-NH

�o
N
H

Scheme 1: Condensated derivatives of isatin
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SMe
Sat. NaHC0

3

68.1%

BocHN ANBoc
6

O

CO=
H
Isatin

Na2C0 3
0 ___ _ _ _ _�
Water
MeOH
33.9%

10% TFA
Quant. Yield

Scheme 2: Di-tert-buroxycarbonyl protection and guanidine derivative creation
pathway
The procedure for the di-Boe protection was taken from literature to prepare
7

intermediate 6. Multiple methods were attempted to create compound 7' as shown in
Table 1. All conditions lead to the mono-Boe 7. Condensation of compound 7 and isatin
provided more than one product towards preparation of 9. The free hydrazone 8 was
prepared and condensed with 6 to obtain compound 9. As seen previously, one tertbutoxycarbonyl group was removed; however compound 9 appeared pure and was still
carried through deprotection in acidic conditions creating the TFA salt 10.
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SMe
BocHN

Base
Solvent

A

6

NBoc

HN

I

►

.,.....NH2

H2N�NBoc
7

Hydrazine
salt

Base

Solvent

1

· H 2S04

NaHC03

MeOH

2

· H 2S04

Triethylamine

MeOH

3

· H 2S04

Na

®oMe

MeOH

4

· 2 HCl

Nae ®oMe

MeOH

5

· H 2S04

Na2C03

Water and MeOH

6

· 2 HCI

Na2C03

Water and MeOH

7

· H2 S04

Sat. NaHC03

CH2Cl2

e

Table 1: Reaction conditions used in attempting guanidine derivative 9.

Biological testing
Correlation of Colony Counts and Optical Density
Colony forming units were correlated with optical density to determine the
5

0D 600 for approximately 5x10 colony forming units (CFUs} to start the MIC assay.
Colony counts were completed for E. coli ATCC ® 25922 and P. aeruginosa Carolina ®
155250A on Luria broth agar plates, and on tryptic soy agar plates for 5. aureus
Carolina ® 155554A. For E.coli, the count of CFUs was best observed on the plate diluted
to a correlation of the 0D 600 from the parent culture and the CFUs gave an 0D 600 at
s

5x10 CFUs. Similar analysis for P. aeruginosa provided an 0D 600 value of 0.000005. For
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5. aureus, the correlation extrapolated to an 00 600 of 0.004. While cultures will contain
some differences and error is expected, the colony count for P. aeruginosa was the only
sample not within error of previously performed colony count data. As a result an 00 600
of 0.0013 was used based on previous data collected within the Christian Melander lab.
Minimum Inhibitory Concentration Assay

Synthesized compounds 1, 2, 4, 8, and 10, were tested within the concentration
ranges from 15 µg/ml to 128 µg/ml with Erythromycin and Penicillin G as controls for
cell death. The MIC assays for E. coli yielded MICs of 128 µg/ml for Erythromycin and
Penicillin G, the positive controls, with no observable cell death for any of the
synthesized compounds or isatin at or below 128 µg/ml. Only Erythromycin proved
toxic to P. aeruginosa at 128 µg/ml, with no observable cell death for the synthesized
compounds or the isatin. 5. aureus proved more susceptible with observed MICs of
0.125 µg/ml for Erythromycin, 128 µg/ml for Penicillin G, 128 µg/ml for isatin, and 32
µg/ml for 4. There was no observable cell death for any of the other synthesized
compounds at the tested concentrations.
Biofilm Inhibition Assay

2-Aminobenzimidozole (2ABI) (Figure 3) was chosen as the control as it is known
to inhibit biofilm formation for P. aeruginosa with an IC50 47 µM. 22 lsatin was tested as it
was the parent molecule for all the derivatives created. Both 2ABI and isatin were tested
for all bacteria. For the biofilm inhibition assays for E.coli, compounds 1, 2, and 10 were
tested. The compounds tested for P. aeruginosa were compounds 1, 2, 10, and 8. For
the assays for 5. aureus the compounds tested were compounds 1, 2, 10, 4, and 8.
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Figure 3: Structure of 2-Aminobenzimidozole (2ABI}

The biofilm inhibition assays for E.coli indicated that both compounds 1 and 2
inhibited biofilm with IC 50 values of 380 µg/ml and 112 µg/ml, respectively {Table2).
The control, 2ABI, compound 3, and isatin were found to promote biofilm. Conversely,
2ABI, compound 8, and isatin were found to be biofilm inhibitors for P. aeruginosa with
IC 50 values of 20 µg/ml, 207 µg/ml, and 12 µg/ml, respectively, while compounds 1
and 2 were found to be biofilm promoters. Compound 10 was found to not affect
biofilm formation. The biofilm inhibition assays for 5. aureus indicated that compounds
3 and 8 inhibit biofilm with IC 50 values of 51 µg/ml and 195 µg/ml, while compound 2

and isatin were found to promote biofilm production. 2ABI was found to not affect
biofilm production for 5. aureus.
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Bacteria

E.coli

P. aeruginosa

S. aureus

Compound MIC (ug/mL) 8 IC 50 (ug/mL) Promoter c
Yes

2ABI

>128

1

>128

380 b

2

> 128

112

10

>128

Yes

Isatin

> 128

Yes

2ABI

>128

1

> 128

Yes

2

> 128

Yes

8

>128

10

>128

Isatin

> 128

2ABI

>128

1

> 128

2

> 128

4

32

8

>128

10

>128

Isatin

128

a 128 was the highest concentration tested.
quadratic c biofilm increase relative to control

30

12

Yes

51
Yes
b

extrapolated from best fit

Table 2: Observed anti-microbial effects.

Conclusions
Within this study, procedures for the creation of isatin derivatives were
developed. These derivatives have been tested against £. coli, P. aeruginosa, 5. aureus
to determine the 0D 600, minimum inhibitory concentration and the effect the
compounds have on biofilm production. Within the MIC assays, only isatin and
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compound 4 were found to cause bacterial death within range of concentrations tested.
Compounds 1 and 2 were found to be biofilm inhibitors for E. coli, while 2ABI,
compound 3, and isatin were found to be biofilm promoters. For the biofilm assays of P.
aeruginosa, it was found that 2ABI, compound 8, and isatin inhibit biofilm production

while compounds 1 and 2 promoter production. Compound 3 was found to have no
effect on the biofilm production of E. coli. 2ABI and compounds 3 and 8 were found to
be biofilm inhibitors for 5. aureus. Compound 2 and isatin were found to be promoters,
while compounds 1 and 4 had no effect on biofilm production.
Looking to the future, in the short term, the results attained from this
investigation for the biofilm assays could be repeated as to verify their accuracy and
determine standard deviations. Also, the MIC assays for the compounds demonstrating
bacterial death could be refined by narrowing concentration ranges closer to the found
MIC. The growth curves need to be created for all observed inhibition concentrations to
evaluate if any of the compounds are influencing cell growth. Another short term
adjustment that could be made is to change the bacteria the compounds were tested
against to give a better understanding of the compounds abilities, possibly adding Gram
positive bacteria since values were improved against 5. aureus.
As a longer term goal, compounds that have shown promise would be tested
against a eukaryotic organism to test whether promising compounds would be toxic to
humans. If not, then they could be tested further for potential use as a replacement for
antibiotics.
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Experimental
General Information
1

Proton nuclear magnetic resonance ( H NMR) and Carbon-13 nuclear magnetic
13

resonance { C NMR) spectra were recorded with a Varian EM 360L NMR spectrometer.
The solvent used was dimethyl sulfoxide-d6. The infrared spectrum was recorded with a
Thermo Scientific Nicolet iSIO. Ultraviolet/Visible (UV) values for biofilm assay were
recorded with a

Biotek Elx808 Multichannel Plate Reader. Melting points were

recorded with a Barnstead Electromantle (EM series). The shaken incubation was
performed in a VWR 1585 shaking incubator set at 37.0 °C and 200 RPM. The stationary
incubation was performed in a Precision Scientific Co oven (Model 17) set to 37 °C.

Compound Synthesis
General Procedure for creation of 1 and 4
To a solution of 1 eq of isatin and EtOH (6.5 ml) was added 1 eq of respective hydrazide
derivative. This mixture was refluxed at 60 °C for thirty minutes, and then allowed to
recrystallize overnight. The pure solid was filtered. 1:Vellow solid (0.481 g, 2.31 mmol,
96.8 % yield); Mp 262 - 282 °C; Rf 0.5 in 50:50 ethyl acetate/ hexanes; IR (acetone film)
3467 (w), 3300 (br), 3235 (br), 3132 (br), 2999(br), 2821(br), 1703(s), 1622(w), 1573 (s),
1
1463(s); H NMR (60 Hz, DMSO-d6)

o 11.73 (1 H, s), 11.10 (1 H, s), 7.61 (2 H, d), 7.34-

6.85 (6 H, m); 13C NMR (15 Hz, DMSO-d6) 6 162.6, 155, 141.5, 131, 130.3, 122.2, 120.3,
120.2, 110.8. 4: Yellow solid(0.011 g, 0.038 mmol, 73.4 % yield); Mp 220 -230 °C; Rf 0.31
in 40:60 ethyl acetate/hexanes; IR (acetone film) 3269 (br) 1735 (s) 1705 (s) 1614 (br)
1497 (s); 1H NMR (60 Hz, DMSO-d6)

o 11(1 H, s), 10.74(1 H, s), 8 (1 H, d), 7.43 (6 H, s),
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7.03 (2 H, d), 5.28 (2 H, d);

1
3C

NMR (15 Hz, DMSO-d6) 6 164.7, 154.7, 154.4, 143.6,

136.1, 132.5, 128.6, 128.3, 126.3, 115.5, 110.5, 67.2.
Procedure for creation of 2
To a solution of 1 eq of isatin and EtOH (6.5 ml) was added 1 eq of thiosemicarbazide
and 1 drop of 6 M HCI. The mixture was refluxed at 60 °C for sixty minutes. The solid was
filtered to obtain a pure yellow solid (0.18 g, 0.796 mmol, 96.7% yield). Mp 284 °C; Rf
0.42 in 50:50 ethyl acetate/hexanes; IR 3516 (br), 3420 (br), 3336 (br), 3265 (br), 3162
1

(br), 1701 (s), 1670 (s), 1621 (s), 1593 (s), 1583 (s), 1463 (s); H NMR (60 Hz, DMSO-d6) 6
12.51 (1 H, s), 11.21 (1 H, s), 9.04 (1 H, s), 8.67 (1 H, s), 7.68 (1 H, d), 7.40- 6.87 (3 H, m);
13 C

NMR (15 Hz, DMSO-d6) 6 178.8, 162.6, 142.4, 132.1, 131.3, 122.3, 120.9, 1229.9,

111.
Procedure for creation of 8
A mixture of 1 eq of isatin, 3 eq of hydrazine sulfate salt, 1.5 eq of sodium carbonate,
MeOH (5 ml), and water (5 ml) was refluxed at 60 °C for two hours and allowed to
recrystallize at room temperature. The solid was vacuum filtered, then triturated in
water and vacuum filtered again to obtain a pure yellow solid (0.158 g, 0.980 mmol,
33.9% yield). Mp 208 °C; Rf 0.55 in 40:60 ethyl acetate/hexanes; IR 3352 (br), 3209(br),
1
2834(w), 1681(s), 1655 (s), 1587(s), 1549(s), 1465(s); H NMR (60 Hz, DMSO-d6) 6 10.68
(2 H, d), 9.65 (1 H, s), 7.45 - 6.84 (5 H, m);
127, 126.2, 122.2, 121.3, 117.4, 109.9.

1

3C

NMR (15 Hz, DMSO-d6) 6 162.8, 138.6,
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Procedure for creation of 10
23
Di-Boe protection of methyl thiourea was carried out as per literature procedure. The
Di-Boe protected 1 eq of thiourea was then refluxed with 1 eq of 8 and MeOH (10 ml,
0.2 M) in an oil bath at 60 °C. Silica was added and the mixture was concentrated. Crude
product was eluted at 40% ethyl acetate/60% hexanes through a silica gel column. The
pure product was then stirred 10% TFA (0.5 ml) and dichloromethane (5 ml).
Chloroform was then added and the reaction was concentrated to provide the solid
yellow TFA salt of the product (0.096 g, 0.319 mmol, quantitative yield). Mp 195 °C; Rf
0.53 in 50:50 ethyl acetate/hexanes; IR 3428 (br) 3114 (br) 1720 (s) 1703 (s) 1638 (w)
1
1612 (s) 1572 (s) 1469 (s); H NMR (60 Hz,DMSO-d6) 10.95 (1 H, s), 8.46 (6 H,s),7.47 6.89 (4 H, m); 13C NMR (15 Hz,DMSO-d6) 164, 157.3, 144.2, 139.5, 133.5, 126.6,121.8,
115,110.9.
Biological Screening
General Colony Count/Optical Density Correlation Procedure
Bacteria were cultured in Mueller-Hinton broth (MHB) media for 6-8 hrs. The cultures
were then diluted by 10 then an optical density at 600 nm (OD 600 ) was recorded.
Bacterial solutions of concentrations at 1/2, 1/4, 1/8, and 1/16 of this solution were
measured for OD600 values. The original bacterial cultures were then plated on agar
plates (Luria broth plates for £. coli and P. aeruginosa, tryptic soy agar plates for 5.
12
7
aureus) at concentrations of 10- through 10- . These plates were then incubated for 16
hrs and plates bearing 100 or less colonies were counted. These bacterial counts were
used to find the bacterial concentration (colony forming units) of the cultures. The
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bacterial concentration was then plotted against the 0D 600 values to extrapolate the
1

5

0D 600 value for a solution of bacteria bearing 5 x 10 CFU ml- • This value can then be
used in the MIC assays for quick determination of starting inoculates.

General Minimum Inhibitory Concentration {MIC) Procedure
5

1

Mueller-Hinton broth (MHB) was inoculated at a concentration of 5 x 10 CFU ml- with
the bacteria. The inoculate was then divided into 1 ml aliquots and test compound was
added to provide the highest tested concentration. 200 µL of test solutions were then
added to the wells 2-7 within the first row of a 96 well polystyrene plate. Cells 1 and 8
were reserved for control lanes of inoculated solutions that were free of test
compounds.

Inoculated media (100 µL) was added to rows 2-12 of the 96-well

polystyrene plate. The test samples were then serially diluted (100 µL transfers) down
their corresponding rows. Between each transfer the samples were mixed 6-8 times by
pipet. Once serial dilution was complete the plate was then sealed with Glad Press and
®

Seal and incubated under stationary conditions at 37

°C.

After 16 hrs MIC values were

recorded as the lowest concentration of the test compound that caused no visible
bacterial growth.

General Biofilm Inhibition Assay Procedure
Overnight cultures of bacteria (E. coli in LB, P. aeruginosa in LB, and 5. aureus in TSB plus
glucose) were diluted to an 0D 600 of 0.01. Test compounds were then diluted into 1 ml
of this bacterial solution at predetermined concentrations.

A 96-well polystyrene plate

was then used horizontally to add 2-100 µL water columns (columns 1 and 12), 4-100 µL
control columns with no compound (columns 5-8), and 6-100 µL compound containing
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lanes in decreasing dosage concentrations (columns 2-4 and 9-11).

The plates were

®

then covered with Glad Press and Seal and incubated under stationary conditions at 37
°C for 24 hrs. The media was then discarded and planktonic bacteria were removed by a
gentle water washing.

Each well was then stained with 125 µL of 0.5% solution of

crystal violet at room temperature for 30 mins. After thoroughly washing away the
excess crystal violet with water the stained biofilm was dissolved in 200 µL of 95%
ethanol. This solution was allowed to sit for 15 mins and 100 µL was transferred to the
corresponding wells of a polystyrene microtiter dish.
quantified by measuring the OD 630 of each well.

Biofilm inhibition was then

Blank wells were used to subtract

background polystyrene adhered stain.
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Appendix
Sample Colony Count Plot
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Graph 1: Optical density verses the concentration of 5. aureus bacteria within the sample, found
with colony count. 0D 600 was found to be 0.004.

Sample Inhibition Plot
y = 0.0011x2 + 0.2048x + 42.956
R2 = 0.939
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Graph 2: Concentration of sample (2ABI) in µM verses the percent biofilm inhibiton of bacterial
sample (P. Aeruginosa). The IC 50 value for this plot was found to be 29.596
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